Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study (Q34810005)

4 August 2017

title

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study (English)

1 reference

4 August 2017

0 references

Bianca Weinstock-Guttman

object named as

Bianca Weinstock-Guttman

3

1 reference

4 August 2017

Victor M Rivera

1

1 reference

4 August 2017

Douglas R Jeffery

2

1 reference

4 August 2017

Daena Bock

4

1 reference

4 August 2017

Fernando Dangond

5

1 reference

4 August 2017

publication date

11 July 2013

1 reference

4 August 2017

1 reference

4 August 2017

volume

13

1 reference

4 August 2017

page(s)

80

1 reference

Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

The influence of rheumatoid arthritis disease characteristics on heart failure.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Cardiovascular disease in rheumatoid arthritis: a step forward

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Acute myeloid leukaemia induced by mitoxantrone: case report

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Patterns of comorbidity in elderly patients with multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Suppression of demyelination by mitoxantrone

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

Vascular disease among hospitalized multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-80

High risk of cardiovascular diseases after diagnosis of multiple sclerosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3710498

Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone

26 October 2018

1 reference

12 December 2020

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

1 reference

12 December 2020

Noninvasive Assessment of Mitoxantrone Cardiotoxicity in Relapsing Remitting Multiple Sclerosis

1 reference

12 December 2020

Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis

1 reference

12 December 2020

Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis

1 reference

12 December 2020

Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone

1 reference

12 December 2020

Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis

1 reference

12 December 2020

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2377-13-80

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference

4 August 2017

1 reference